Advances in the discovery and development of melanoma drug therapies

被引:16
作者
Chanda, Monica [1 ]
Cohen, Mark S. [1 ,2 ,3 ]
机构
[1] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
Melanoma; chemotherapy; targeted therapies; immunotherapy; clinical trials; immune checkpoint inhibitors; BRAF; MEK inhibitors; IMMUNE-CHECKPOINT INHIBITORS; IN-TRANSIT MELANOMA; METASTATIC MELANOMA; MEK INHIBITORS; TALIMOGENE LAHERPAREPVEC; STAGE-III; BRAF; CANCER; NIVOLUMAB; PD-1;
D O I
10.1080/17460441.2021.1942834
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Therapeutic strategies for melanoma have evolved significantly over the last decade shifting from cytotoxic chemotherapies like dacarbazine to targeted therapies and immunotherapies including immune checkpoint inhibitors. These new drug therapies have improved overall as well as progression-free survival, lowering the mortality of this cancer for melanoma patients with advanced disease. Newer strategies incorporate combination therapies that harness synergies between mechanisms of anticancer efficacy as well as help overcome resistance issues of monotherapies, which remain a challenge. Areas covered This review looks at each class of drug therapy for melanoma and provides an overview of the preclinical mechanism of action, the clinical efficacy data, and their applications in combination therapy regimens. NCCN treatment guidelines, safety, toxicity, and immune-related adverse events are also described as well as a note on cost. Expert opinion Numerous ongoing trials continue to evaluate the role of novel therapies and combinations for this challenging disease and understanding their mechanism of action, risks, benefits, and treatment guidelines can help care providers and patients have a more comprehensive and tailored discussion of treatment options and expectations.
引用
收藏
页码:1319 / 1347
页数:29
相关论文
共 128 条
[1]   Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases [J].
Angela, Yenny ;
Haferkamp, Sebastian ;
Weishaupt, Carsten ;
Ugurel, Selma ;
Becker, Juergen C. ;
Oberndoerfer, Florian ;
Alar, Vesna ;
Satzger, Imke ;
Gutzmer, Ralf .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (07) :1187-1194
[2]  
[Anonymous], 2017, AUST PRESCR, V40, P30, DOI 10.18773/austprescr.2016.095
[3]  
[Anonymous], 2017, MULTIDISCIPLINARY RE
[4]  
[Anonymous], 2020, ENC DRUG INF
[5]  
[Anonymous], 2020, ALD DRUG INF
[6]  
[Anonymous], 2012, PHARM TOX NDA REV EV
[7]  
[Anonymous], 2020, NAN ALB BOUND PACL D
[8]  
[Anonymous], 2020, TEM DRUG INF
[9]  
[Anonymous], 2020, DABR DRUG INF
[10]  
[Anonymous], 2020, CARB DRUG INF